
Downloaded from: http://researchonline.lshtm.ac.uk/628844/

DOI:
Cryptococcal meningitis – a neglected killer

In this issue of the SAMJ, Lessells et al.1 highlight the unacceptably high mortality due to HIV-associated cryptococcal meningitis (CM) in routine clinical practice in South Africa. CM is now the most common cause of adult meningitis in much of central and southern Africa, accounting for 63% of all microbiologically confirmed cases in the largest published series.2 There are an estimated 720 000 cases annually in sub-Saharan Africa, leading to 504 000 deaths;3 expanding access to antiretroviral therapy (ART) has not yet led to a decline in these numbers.4

In research settings in South Africa, utilising optimal amphotericin B-based treatments, acute mortality of CM is between 24 and 37%.5,6 Lessells et al. suggest that, in routine care settings, mortality rates are higher.7 From their study conducted at Hlabisa Hospital in rural KwaZulu-Natal, they report 41% in-hospital mortality (all of which deaths occurred within 30 days of admission), which is in keeping with data from Johannesburg, where only 33% of CM patients were known to be alive and under follow-up at 12 weeks (Govender N, unpublished). Of even greater concern is their finding that only 11% of CM patients were alive and taking ART at 2 years. Although high early mortality rates are reported in African ART programmes, data from research settings in Cape Town show that, provided patients survive the acute illness, long-term survival of CM patients can be good once they have been established on ART.6

The excessive CM mortality in routine care compared with research settings is probably owing in part to patients’ difficulties accessing overloaded health care services. This issue almost certainly leads to delays in diagnosis when patients develop CM symptoms, resulting in advanced disease at presentation – a factor consistently identified as a risk for mortality. A further contributor is the lack of availability of amphotericin B (the optimal initial treatment for CM) in many hospitals. Outcomes with the alternative, fluconazole monotherapy as initial CM treatment, are poor.7 Lessells et al. report that only 35% of patients in their cohort received any amphotericin B, and only 8% received what is considered the optimal 2-week course. Unfortunately, this situation appears to be the norm in South Africa, accounting for 63% of all microbiologically confirmed cases, which is thought to result from impaired insight, cognition, mobility or volition.14 Thirty-four per cent of patients in the Lessells study had a depressed level of consciousness at the time of admission and, even though this may improve during CM treatment, many patients still have impaired cognition during their hospital stay. This impairs patients’ ability to comprehend counselling regarding the need for ongoing fluconazole, ART and outpatient follow-up. In addition, our experience suggests that insufficient time is spent counselling patients in this regard in their own language during an admission for CM.

What needs to be done? The good news is that, despite the poor outcomes described in the KwaZulu-Natal cohort, a series of straightforward steps could markedly improve outcomes, even with the currently available treatment options. Clinicians need to have a low threshold for suspecting CM, and all known or suspected HIV-infected patients with a new headache should have a diagnostic lumbar puncture. Amphotericin B should be made available to all clinicians treating such patients, and these clinicians should be educated about the importance of its role in initial therapy, and about the steps needed to monitor for and prevent its adverse effects. Manometers should be available, and clinicians must routinely measure CSF opening pressure in CM patients and manage it according to established guidelines. Importantly, in addition to improving inpatient treatment, subsequent linkage into outpatient ART services must be strengthened. This requires both a streamlining of the referral process with improved communication between inpatient and primary care providers, and specific counselling for patients, emphasising the importance of ongoing fluconazole treatment, the need for ART, and details about where to attend for outpatient care. Involving relatives or friends as treatment supporters during the admission, who could assist with ensuring that such vulnerable patients get to their outpatient appointments, assist with adherence to ART and fluconazole, and bring patients for medical attention if they deteriorate, could make an important difference to outcomes. Health care services must recognise and make provision for the fact that patients who have had an acute opportunistic infection (particularly those that involve the CNS) are vulnerable and need special attention in order to get them onto ART and specifically support them through the first months of treatment. Additional input, both medically and socially, during this early treatment period would pay dividends in terms of long-term survival.

More work is needed to develop simple to use, point-of-care diagnostic tests for CM, to develop improved initial treatments and to define the optimal timing of ART initiation. There is also the exciting possibility that much CM-related morbidity and mortality could be prevented by routine cryptococcal antigen screening of asymptomatic patients entering ART programmes.15 But, as Lessells and colleagues clearly demonstrate, CM is exacting a high toll in South African patients now. We can and must do better with the tools we already have.

The Southern African HIV Clinicians Society Guidelines for the Prevention, Diagnosis and Management of Cryptococcal Meningitis are accessible online at: http://sahivsoc.org/index.php?option=com_docman&task=cat_view&gid=18&dir=DESC&order=date&Itemid=67&limit=5&limitstart=5
JNJ and GM are supported by the Wellcome Trust, London, UK (WT081794 and WT081667).

Joseph Jarvis
Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, and Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town
Infectious Diseases Unit, G F Jooste Hospital, Cape Town
Centre for Infection, Department of Cellular and Molecular Medicine, St George’s University of London

Graeme Meintjes
Division of Infectious Diseases and HIV Medicine, Department of Medicine, and Institute of Infectious Disease and Molecular Medicine, University of Cape Town
Infectious Diseases Unit, G F Jooste Hospital, Cape Town
Department of Medicine, Imperial College, London

Corresponding author: J Jarvis (joejarvis@doctors.net.uk)

References